Merus NV Interim Clinical Data Call Transcript
Good day and thank you for standing by. Welcome to the Merus Investor Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. (Operator Instructions)
I would now like to hand the conference over to your first speaker today to Kathleen Farren, Investor Relations and Corporate Communications Manager. Please go ahead.
Good evening everyone. Thank you for joining our call during this very busy ASCO weekend to discuss zenocutuzumab or Zeno and the data presented earlier today NRG1 fusion cancer.
The slide presentation we are presenting tonight is also available on our website at www.merus.nl. On this call we will also be making certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, and events and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |